Global Precision Medicine & Genomics Market — Intelligence Report

The precision medicine and genomics market is entering a scale-up phase, moving from specialist research and oncology-led adoption toward broader integration across diagnostics, therapeutics, drug development, and population health. Market expansion is being driven by the convergence of lower sequencing costs, biomarker-led treatment pathways, companion diagnostics, pharmacogenomics, and expanding payer and provider acceptance of molecularly guided care. Published market benchmarks indicate the global precision medicine market is projected to grow from USD ••• billion in 2025 to USD ••• billion by 2035, representing a CAGR of ••% [S3].

Genomics remains the foundational technology layer for precision medicine. Evidence indicates the genomics segment held the largest share of the precision medicine market in 2025 at ••%, reflecting its central role in identifying genetic variation, improving diagnostic accuracy, and supporting individualized treatment selection [S2]. In parallel, the genomics market itself is forecast to expand from USD ••• billion in 2025 to USD ••• billion by 2030 [S9], reinforcing the sector’s role as both an enabling infrastructure market and a standalone growth category.

Clinical demand is strongest in oncology, rare diseases, inherited disorders, reproductive health, and pharmacogenomics, where molecular stratification can materially affect treatment selection, trial eligibility, and patient outcomes. Multi-omics approaches are also broadening the market from single-gene or panel-based testing toward integrated datasets combining genomics, proteomics, metabolomics, and other molecular information. This evolution is expanding the addressable opportunity beyond sequencing instruments and tests into interpretation platforms, clinical decision support, specialty diagnostics, data infrastructure, and therapy-development services.

North America remains the leading regional market, supported by advanced healthcare infrastructure, high R&D intensity, mature reimbursement pathways for selected molecular diagnostics, and strong adoption among academic medical centers and biopharmaceutical sponsors. Asia Pacific is becoming the highest-momentum growth region, supported by expanding genomics capacity, national health initiatives, rising oncology burden, and increasing private-sector investment. One cited genomics outlook identifies Asia Pacific as a particularly lucrative region, expected to expand at a ••% CAGR in genomics [S1].

Nexvora Intelligence developed this opening outlook through triangulation of published market benchmarks, segment-level evidence, regional adoption indicators, therapy-area demand signals, and proprietary healthcare market modeling.

The market definition includes precision medicine diagnostics, genomics-enabled clinical testing, targeted therapy enablement, pharmacogenomics, multi-omics applications, and related data and interpretation infrastructure, while adjusting for overlap between genomics and broader precision medicine spending.

Modeled estimates reflect Nexvora’s assessment of adoption curves, reimbursement progression, clinical utility evidence, regional healthcare capacity, and investment flows across diagnostics and therapeutics.

Figures cited with source markers are drawn directly from the evidence provided; all other quantitative values are Nexvora modeled estimates and should be interpreted as directional ranges rather than reported external statistics.